Fibrocell Science Inc (FCSC) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Fibrocell Science Inc (NASDAQ:FCSC) in a research note issued to investors on Thursday. HC Wainwright currently has a $7.60 target price on the stock.

FCSC has been the subject of several other reports. Canaccord Genuity restated a buy rating and set a $7.00 target price (up from $3.00) on shares of Fibrocell Science in a research note on Monday, September 11th. ValuEngine upgraded Fibrocell Science from a strong sell rating to a sell rating in a research note on Thursday, June 15th. Finally, Zacks Investment Research upgraded Fibrocell Science from a hold rating to a buy rating and set a $4.25 target price for the company in a research note on Wednesday, July 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $5.21.

Shares of Fibrocell Science (NASDAQ FCSC) opened at 2.93 on Thursday. Fibrocell Science has a one year low of $1.57 and a one year high of $4.64. The stock’s market capitalization is $43.12 million. The firm’s 50-day moving average price is $3.01 and its 200-day moving average price is $2.80.

Fibrocell Science (NASDAQ:FCSC) last announced its earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). Equities research analysts anticipate that Fibrocell Science will post ($2.17) EPS for the current fiscal year.

WARNING: This piece of content was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/09/fibrocell-science-inc-fcsc-stock-rating-reaffirmed-by-hc-wainwright.html.

An institutional investor recently raised its position in Fibrocell Science stock. Creative Planning grew its holdings in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 395.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund o

FCSC has been the subject of several other reports. Canaccord Genuity restated a buy rating and set a $7.00 target price (up from $3.00) on shares of Fibrocell Science in a research note on Monday, September 11th. ValuEngine upgraded Fibrocell Science from a strong sell rating to a sell rating in a research note on Thursday, June 15th. Finally, Zacks Investment Research upgraded Fibrocell Science from a hold rating to a buy rating and set a $4.25 target price for the company in a research note on Wednesday, July 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $5.21.

Shares of Fibrocell Science (NASDAQ FCSC) opened at 2.93 on Thursday. Fibrocell Science has a one year low of $1.57 and a one year high of $4.64. The stock’s market capitalization is $43.12 million. The firm’s 50-day moving average price is $3.01 and its 200-day moving average price is $2.80.

Fibrocell Science (NASDAQ:FCSC) last announced its earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). Equities research analysts anticipate that Fibrocell Science will post ($2.17) EPS for the current fiscal year.

WARNING: This piece of content was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://ledgergazette.com/2017/10/09/fibrocell-science-inc-fcsc-stock-rating-reaffirmed-by-hc-wainwright.html.

An institutional investor recently raised its position in Fibrocell Science stock. Creative Planning grew its holdings in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 395.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 61,090 shares of the company’s stock after buying an additional 48,755 shares during the period. Creative Planning owned 0.42% of Fibrocell Science worth $245,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 54.70% of the company’s stock.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply